Zemen Radar

Ocean waters cover over 70% of the earth and present significant opportunities for renewable energy systems. Ocean Energy Technologies and Components Worldwide contains comprehensive data on the U.S. and world market for the three primary Ocean Energy Technology systems: Tide Energy, Wave Energy and Ocean Thermal Energy. The report also addresses the emerging potential of Salinity Gradient systems. The report identifies key trends affecting the marketplace, along with trends driving growth, and also profiles major domestic and global marketers and geographic hot spots for ocean energy technology implementation.

This SBI study presents a comprehensive overview of the growing market for ocean energy technologies in the United States and throughout the world. Falling within the parameters of this study are all ocean energy technology systems and products. This study includes both public and privately funded systems that are in development or have already been installed. This study also includes emerging systems that are in the early development stages.

Global energy consumption amounts to over 17,400 Terawatt hours per year, with United States’ use alone accounting for approximately11,200 Terawatt hours per year. Ocean energy technology has the potential to generate over 93,100 terawatt hours/year with the two most viable options being wave technology and thermal gradient technology. Wave Energy technology alone has the potential to produce up to 80,000 TWH/year, while OTEC could produce up to 10,000 TWH/year. Salinity Gradient technology, still an emerging science, has the potential to produce 2000 TWH/year. Given the Obama administration’s commitment to green technology and renewable energy alternatives, the outlook for 2009-2010 is very positive for increased investment in both domestic and global ocean energy developments.

In September 2008, New York City installed the first Tidal-Power Turbine system in the United States. As part of a plan for New York to generate up to 80% of the city’s power from renewable energy sources, the completed Tidal-Power Plant is expected to provide power for up to 10,000 households. New York’s Tidal-Power program shows how ocean energy technology is quickly catching up to the more familiar renewable wind and solar power sources.

In Aguçadoura, Portugal, the successful installation of the world’s first multi-unit wave farm will generate 2.5 MW, enough to power 1500 homes. The wave tidal energy market alone could be worth over 0 billion per year. In Hawaii, Taiwan Industrial Technology has entered into collaboration with Lockheed Martin to develop a 10MW Ocean Thermal Energy Conversion (OTEC) pilot plant.

Within the United States, Maine and Alaska offer the best conditions for tidal power plants, while Hawaii and the Atlantic coast have the tropical conditions required for Ocean Thermal Energy Conversion. Recent tests along northern California’s Redwood Coast indicate that the west coast could be an ideal area for testing wave energy systems. While the U.S. is among the global leaders in Ocean Wave and Tidal Current developments, the U.K. dominates the field as of 2008. India and Japan are the global leaders in Ocean Thermal Energy Conversion, while Mexico and Norway are among the initial investors in Salinity Gradient systems.

Report Methodology

The information in Ocean Energy Technologies and Components Worldwide is based on primary and secondary data from the U.S. Energy Information Administration, the European Ocean Energy Association, the International Energy Agency and the Sustainable Energy Coalition, along with information from trade associations such as the Ocean Renewable Energy Coalition and business journals, company literature and websites, and research services such as Simmons Market Research Bureau.

What You’ll Get in This Report

Ocean Energy Technologies and Components Worldwide makes important predictions and recommendations regarding the future of this market, and pinpoints ways current and prospective players can capitalize on current trends and spearhead new ones. No other market research report provides both the comprehensive analysis and extensive data that Ocean Energy Technologies and Components Worldwide offers. Plus, you’ll benefit from extensive data, presented in easy-to-read and practical charts, tables and graphs.

How You’ll Benefit from This Report

If your company is already doing business in the Ocean Energy Technology market, or is considering taking the plunge, you will find this report invaluable as it provides a comprehensive package of information and insight not offered in any other single source. You will gain a thorough understanding of the current market for four types of ocean energy technology, as well as projected markets and trends through 2013.

This report will help:
•    Entrepreneurs and Investors identify market opportunities and gain a better understanding of which types of areas benefit most from ocean energy technology.
•    Research and development professionals stay on top of competitor initiatives and explore demand for ocean energy technology.
•    Green Marketing and Advertising agencies working with clients in the green energy market understand the potential impact of ocean energy technology and the advantages for coastal cities.
•    Business development executives understand the dynamics of the ocean energy technology market and identify possible private and government partnerships.

Information and research center librarians provide market researchers, brand and product managers and other colleagues with the vital information they need to do their jobs more effectively.

Modern 3D printer technologies use a printing process that creates 3D objects with a 3D printer. This is also known as additive manufacturing. The printer will produce a prototype of an object. In addition, the 3D printer is affordable, user friendly and quicker than other technologies. Also, it is possible with this type of technology to print parts of a material in a single process. Nowadays, 3D printers are more affordable for small and medium scale businesses. Businesses are able to use rapid prototyping at their office location.

Before the development of the 3D technology, it was a lengthy process to develop a prototype of a material. During this time, it would take expensive tools, man power and machinery to create a model of a product. With the development of rapid prototyping, it became more affordable for businesses to develop a model.

Inkjet printing is one form of the faster types of modern 3D printing technologies that prints models or prototypes in color. Inkjet printing uses power to be creative and develop a shape. Many biotech firms and academies are looking at using 3D technology for tissue engineering purposes. In addition, organs and body parts are created using inkjet printing. Also, the creations of the body parts are created in one production. This type of technology can help with organ replacements like a hip replacement. The artificial body part created with this process will have the same dimensions as the original body part. This field of technology is called computer aided tissue engineering, organ printing or bio printing.

Other 3D technologies

Some other 3D technologies are 3D scanning. In addition, 3D scanning is the duplication of a factual object without help of a molding method. Other applications of 3D technology can be used to create furniture pieces for homes and modern businesses. As well as, this type of technology is used in architectural design. It is very hard to build and glue architectural designs by hand. You will have to handle the pieces with care or risk the possibility of the design being ruined. The development of 3D technology eliminates this problem. 3D technology makes its possible to create a good design with the exact length, shape, size, width and form. Also, you will be able to evaluate project and the ability see a finished model before the project is completed.

Many schools and university are using 3d technology to teach their students about developing and designing models. This is a good advantage for students because students will learn how to use high end technologies. Also, the students will push designing to the next level with 3D technology. Some of the advantages of this type of technology are the ability to create quick results and its user friendly. Modern 3D printer technologies can save on time and cost to produce a single model of a product.

Read more: 3D Printing Blog

More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have lead to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.

STUDY GOALS AND OBJECTIVES

To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.
To identify major drivers and restraints of the market
To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.
To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.
To analyze trends and forecasts of drug delivery market and its segments
To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.
To analyze opportunities in the market for stakeholders
To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market
To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.
To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World
To provide comprehensive analysis of top players in the drug delivery technology market.
To effectively scope out and justify evaluation and provide sufficient basis of ranking top ten drug delivery technologies.

SCOPE AND FORMAT

The report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:

Oral drug delivery technologies
Injectable drug delivery technologies
Pulmonary drug delivery technologies
Transdermal drug delivery technologies
Other drug delivery technologies

The report also focuses on the emerging drug delivery technologies and mechanisms.

INTENDED AUDIENCES

Drug delivery technology – manufacturers, suppliers and dealers
Pharmaceutical and biotech companies
Healthcare providers
Potential investors in the drug delivery technology market

INFORMATION SOURCES

Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.

Learn How Microsoft Is Balancing Information Communication Technology at the 2008 Government Technologies Conference and Expo

March 25, 2008 – Toronto, Canada – John Weigelt, National Technology Officer, Microsoft Canada, will be keynoting at the 2008 Government and Health Technologies Conference and Expo, taking place April 15 -16, 2008 at the Design Exchange in Toronto Ontario.

John Weigelt will discuss the fundamental issues facing government and healthcare today – achieving the right balance between ICT and the growing demands of the technically savvy citizen and business and the critical needs of patients and healthcare workers.

Microsoft believes that the time has come for a serious re-examination of the ICT options facing government and healthcare organizations, with a tide of increasing expectation and massively more technical capability, the trick is to ensure that our governments and hospitals are waving and not drowning in the turbulent mix.

So, register now to learn more about the Microsoft Solutions and Strategies for government and healthcare to embrace technology to meet the needs of patients and citizens alike while improving internal efficiencies and the jobs of your employees. This strategies and solutions are built with research driven data, market-proven Microsoft infrastructure components, uses open standards, and includes a set of common transactions that enable critical functions to be rapidly provided to citizens, patients, businesses and your employees.

This session is designed specifically for Microsoft Canada to gain insight from our strategic Municipal Government Chief Information Officers and Senior IT decision makers around its CGF and its key building blocks impacting Municipalities: Solution Oriented Architecture and Enterprise Application Integration, Communication and Collaboration, Security, Compliance and Privacy, as well as overall management.

The Microsoft Connected Government Framework is designed to assist municipalities to develop corporate infrastructure environments that will support the transformational technology projects across the breadth of their organization. The CGF helps ensure that value invested in current legacy applications continues to be realized while municipalities improve and update their solutions to deliver superior value to the constituents.

To register for Early-Bird Passes please visit http://gov.wowgao.com/registration OR call (416) 292-0038 Ext. 812.

About Microsoft Corporation

Microsoft Corporation (NASDAQ “MSFT”) is the worldwide leader in software, services and Internet technologies for personal and business computing.

Microsoft Canada Co. was founded in 1985. As the Canadian subsidiary of Microsoft Corporation in Redmond, Washington, the company provides sales, marketing, consulting and local support services in French and English. Microsoft Canada has grown from five people in 1985 to more than 900 employees. It also has strong relationships with more than 24,000 partners across Canada. More than 1,100 of these are Microsoft Certified Partners, and over 200 are Gold Certified Partners. Headquartered in Mississauga, Microsoft Canada has regional offices in Toronto, Vancouver, Calgary, Edmonton, Winnipeg, Ottawa, Montreal, Quebec and Halifax.

About the 2008 Government and Health Technologies Conference & Expo:

The 2008 Government and Health Technologies Conference and Expo will focus on the latest IT products and solutions being developed and sought after in the healthcare and public service sector, including Web 2.0, Patient Monitoring Systems, Document Management, Business Intelligence, Mobile Data Systems, RFID Solutions, Biometrics and much more.

As one of Canada’s leading annual IT conference and exposition, the event features ground breaking IT applications that aim to educate key IT professionals, Government officials, developers, architects, engineers and medical professionals with the necessary tools and techniques for the reliable, effective management of all public information services across Canada. For more information about the event, please visit http://gov.wowgao.com

About WowGao Inc.

WowGao Inc. is an award winning leading event management company that produces, since 2003, internationally renowned conferences and expositions that address the latest innovations and developments in the information technology industry. Our featured events include:

Government & Health Technologies Conference and Expo, April 15 & 16, 2008

Wireless & Mobile Expo and Conference, July 15 & 16, 2008

RFID Forum, July 15 & 16, 2008

Financial Services Technology Forum, October 2008

For more information about the events, please visit http://www.wowgao.com/

For conference inquiries:

Conference Producer

(416) 292 – 0038 ext. 840 | conference@wowgao.com

WowGao Inc. | www.wowgao.com

Learn How Microsoft Is Balancing Information Communication Technology at the 2008 Government Technologies Conference and Expo

March 25, 2008 – Toronto, Canada – John Weigelt, National Technology Officer, Microsoft Canada, will be keynoting at the 2008 Government and Health Technologies Conference and Expo, taking place April 15 -16, 2008 at the Design Exchange in Toronto Ontario.

John Weigelt will discuss the fundamental issues facing government and healthcare today – achieving the right balance between ICT and the growing demands of the technically savvy citizen and business and the critical needs of patients and healthcare workers.

Microsoft believes that the time has come for a serious re-examination of the ICT options facing government and healthcare organizations, with a tide of increasing expectation and massively more technical capability, the trick is to ensure that our governments and hospitals are waving and not drowning in the turbulent mix.

So, register now to learn more about the Microsoft Solutions and Strategies for government and healthcare to embrace technology to meet the needs of patients and citizens alike while improving internal efficiencies and the jobs of your employees. This strategies and solutions are built with research driven data, market-proven Microsoft infrastructure components, uses open standards, and includes a set of common transactions that enable critical functions to be rapidly provided to citizens, patients, businesses and your employees.

This session is designed specifically for Microsoft Canada to gain insight from our strategic Municipal Government Chief Information Officers and Senior IT decision makers around its CGF and its key building blocks impacting Municipalities: Solution Oriented Architecture and Enterprise Application Integration, Communication and Collaboration, Security, Compliance and Privacy, as well as overall management.

The Microsoft Connected Government Framework is designed to assist municipalities to develop corporate infrastructure environments that will support the transformational technology projects across the breadth of their organization. The CGF helps ensure that value invested in current legacy applications continues to be realized while municipalities improve and update their solutions to deliver superior value to the constituents.

To register for Early-Bird Passes please visit http://gov.wowgao.com/registration OR call (416) 292-0038 Ext. 812.

About Microsoft Corporation

Microsoft Corporation (NASDAQ “MSFT”) is the worldwide leader in software, services and Internet technologies for personal and business computing.

Microsoft Canada Co. was founded in 1985. As the Canadian subsidiary of Microsoft Corporation in Redmond, Washington, the company provides sales, marketing, consulting and local support services in French and English. Microsoft Canada has grown from five people in 1985 to more than 900 employees. It also has strong relationships with more than 24,000 partners across Canada. More than 1,100 of these are Microsoft Certified Partners, and over 200 are Gold Certified Partners. Headquartered in Mississauga, Microsoft Canada has regional offices in Toronto, Vancouver, Calgary, Edmonton, Winnipeg, Ottawa, Montreal, Quebec and Halifax.

About the 2008 Government and Health Technologies Conference & Expo:

The 2008 Government and Health Technologies Conference and Expo will focus on the latest IT products and solutions being developed and sought after in the healthcare and public service sector, including Web 2.0, Patient Monitoring Systems, Document Management, Business Intelligence, Mobile Data Systems, RFID Solutions, Biometrics and much more.

As one of Canada’s leading annual IT conference and exposition, the event features ground breaking IT applications that aim to educate key IT professionals, Government officials, developers, architects, engineers and medical professionals with the necessary tools and techniques for the reliable, effective management of all public information services across Canada. For more information about the event, please visit http://gov.wowgao.com

About WowGao Inc.

WowGao Inc. is an award winning leading event management company that produces, since 2003, internationally renowned conferences and expositions that address the latest innovations and developments in the information technology industry. Our featured events include:

Monoclonal antibodies form the fastest growing segment of the pharmaceutical industry, with total annual sales expected to top billion in the next four years. 23 full-size monoclonal antibodies and three monoclonal antibody fragments have been launched so far, several having quickly reached ‘blockbuster status’ (annual sales of over billion). Between 1995 and 2007, the number of monoclonal antibody-based drug candidates entering clinical trials more than tripled, and this expansion is continuing.

This report explains what monoclonal antibodies are, and why large pharmaceutical companies are investing so heavily both in developing such drugs internally and acquiring monoclonal antibody candidates from others. More than 80 popular and emerging technologies are named, explained and illustrated with original full-color diagrams.

The newest wave of drug candidates based on these technologies can be seen in more than 200 case studies, which identify every commercial company known to have carried out preclinical studies of therapeutic monoclonal antibodies in the last year. Finally, prospects and challenges for the future of this field are discussed, with opinions from scientific pioneers and industry leaders.

Key features of this report

• Illustrated ‘beginners guide’ to monoclonal antibodies: What they are, how they are made and why they hold such great promise for the treatment of disease.

• More than 80 descriptions of proprietary technologies currently in use around the world to select produce and re-engineer monoclonal antibodies.

• More than 30 original, full-color diagrams illustrating the science and technology of monoclonal antibodies, both as they appear in nature and in the myriad new forms now being assessed in preclinical trials.

Scope of this report

• Understand the basic qualities of monoclonal antibodies and how these qualities translate into unique medical and commercial features for drug candidates.

• Appreciate the challenges and risks of monoclonal antibodies, as well as their promise.

• Assess promising new technologies for investment or in-licensing.

• Identify which companies are involved in this field, and what they are doing.

• Predict the kinds of drug that will enter clinical trials in the next 1-4 years and may reach the market in the next 5-10 years.

Key Market Issues

• New monoclonal antibodies can be used to target new disease processes that are not currently addressed by any other therapies, thereby accessing market areas with high unmet demand.

• The inherent specificity and predictability of monoclonal antibodies have been shown to shorten drug development times and increase rates of success in preclinical and clinical trials, relative to non-biological ‘small molecule’ drugs.

• High barriers to entry currently prevent many new companies from entering this field. The techniques now used to create, select and modify monoclonal antibodies for human therapeutic use are protected by intellectual property, which the originators defend vigorously. However, several early patents on fundamental techniques will expire very soon.

Key findings from this report

• Early challenges relating to immunogenicity, tissue penetration, administration and production of monoclonal antibodies are being addressed by myriad new technologies.

• The competitive benefits of identifying and addressing new therapeutic targets continue to provide incentives for new target selection and monoclonal antibody identification programs.

• Established techniques for ‘humanization’ of non-human monoclonal antibodies remain popular, despite the rise of newer ‘fully human’ monoclonal antibody technologies. This may be due to the robust nature of the earlier technologies and/or the imminent expiries of key patents.

• Genetic engineering methods and novel ‘host cell’ production systems are being used to optimize and modify functions of monoclonal antibodies. Proprietary platforms using these methods have been widely licensed to many of the major players in the biopharmaceutical industry.

Key questions answered

• What are monoclonal antibodies, and what can they do?

• Why are so many companies developing them as therapeutic agents?

• Which companies are currently working to validate and develop the latest generation of drug candidates based on monoclonal antibodies?

• What technological and regulatory challenges face these companies in developing such candidates and bringing drugs to market?

Table of Content:

Executive summary 16

An introduction to monoclonal antibodies 16

Identifying non-human monoclonal antibodies 17

Optimizing full-length antibodies 17

Fully human monoclonal antibodies 18

Antibody conjugates 19

Novel binding molecules derived from antibodies 20

Chapter 1 An introduction to monoclonal antibodies 22

Summary 22

Introduction 23

Antibodies in nature 23

Advantages of monoclonal antibodies as drugs 29

Target range 29

Predictability 30

Pharmacokinetics 30

Technology protection 30

Challenges and opportunities for the next generation of monoclonal antibodies 31

Target selection 31

Species specificity 33

Pharmacokinetics 34

Manufacture 34

Monoclonal antibody drugs already at market 35

Orthoclone OKT3 35

Remicade 36

Rituxan 36

Zenapax 37

Synagis 37

Humira 37

Vectibix 38

Simponi 38

Lucentis 38

Cimzia 39

Tysabri 39

Preclinical development of therapeutic drugs 40

Proof of concept 40

Safety profile 40

Conclusions 42

Chapter 2 Identifying non-human monoclonal antibodies 46

Summary 46

Introduction 47

Technology platforms 47

Hybridoma technology 48

RabMAbs 48

SLAM 48

Human Response Platform 49

DIAAD 49

ImmuneY2 50

iMAB 50

Fusion Expression Technology 51

ProMIS 51

AbScreen 51

AbProt 52

BioArctic platform 52

FunctionFIRST 52

Case studies 52

Abbott Labs 53

AbGenomics 53

Alethia 53

Amorfix 53

Arrowsmith Technologies 54

AVEO 55

BioSceptre 55

Canadian Bio Med Systems 55

Cangene 56

CellAct 56

CoGenesys 57

Crucell 57

CSL 58

Daewoong 58

DKFZ 58

Epitomics 59

Fusion Antibodies 59

Ganymed Pharmaceuticals 60

GeNeuro 60

Genitope 60

GSK 61

Heat Biologics 61

Immuno-Biological Labs 61

ImmunoGen 62

Immutep 62

InflaRx 63

Innate Pharma 63

Inotek 63

Intercell 64

LigoCyte 64

MedImmune 64

Morphotek 65

NeoGenix 65

Northwest Biotherapeutics 66

Novartis 66

Novo Nordisk 67

OncoMed 67

Perseis Therapeutics 67

Pfizer 68

Pharma Research Toronto 69

Prana Biotech 69

Quest PharmaTech 69

Recepta Biopharma 69

Receptor-Logic 70

Roche 70

Shanghai CP Guojian 71

Suzhou Stainwei Biotech 71

Therapure 71

ThromboGenics 71

Thrombotargets 72

Tolerx 72

Trillium 73

Vaccinex 73

Wilex 73

ZymoGenetics 74

Conclusions 81

Chapter 3 Optimizing full-length antibodies 84

Summary 84

Introduction 85

Technology platforms 86

Chimeric antibodies 86

CDR grafting 88

SMART 90

Superhumanisation 90

Framework Patching 91

Composite Human Antibody 91

ATLAb 92

Humaneering 92

MLG 93

DeImmunisation 93

Humanation 93

Human Engineering 94

FcX 94

The LEX System 94

Potelligent 94

Complegent 95

BestMAb 97

ImmunoBody 97

EB66 97

Synageva Expression Platform 98

XmAb 98

Sugar Engineered Antibodies 99

Wox 99

Case studies 101

Abbott Labs 101

Advanced Immune Therapeutics 102

Alder Biopharm 102

Alethia 103

Alexion 103

Antisoma 103

Arana 104

Attenuon 105

AVEO 106

BioArctic Neuroscience 106

Biogen Idec 106

Biolex 107

BioXell 108

China Synthetic Rubber Corp 108

CSL 108

CureTech 109

Direvo 109

DSX 109

Eli Lilly 110

Epitomics 110

Faron Pharm 110

Femta Pharm 110

Forerunner Pharma Research 111

Fusion Antibodies 111

Galaxy Biotech 112

Galileo Oncologics 112

Genentech 113

Glenmark 113

GlycoForm 114

Glycotope 114

ImmunoCellular Therapeutics 114

Immunomedics 115

Innate Pharma 115

InNexus Biotech 115

Intellect Neurosciences 116

Isu Abxis 116

Janssen Alzheimer Immunotherapy 116

KaloBios 117

Keel Pharm 117

LigoCyte 117

Lpath 117

Mabion 118

MacroGenics 118

MaimoniDex 119

MAT Biopharma 119

MedImmune 119

Medtronic 120

Micromet 120

NKT Therapeutics 120

Opsona 121

Percipio 121

Pharma Research Toronto 122

ProtAb 122

Scancell 123

Selexys 123

SinoMab Bioscience 124

Synageva 124

TaiMed 124

Trillium 125

United Biomedical 125

Vascular Pharm 125

VasGene 126

Vegenics 126

Vybion 126

Xencor 127

Conclusions